Tagraxofusp

Tagraxofusp is a targeted biologic drug used in the treatment of certain types of cancer. It is a fusion protein consisting of the diphtheria toxin and interleukin-3 (IL-3). IL-3 is a cytokine that helps stimulate the growth and differentiation of white blood cells, including certain types of leukemia cells. Tagraxofusp is designed to selectively deliver the diphtheria toxin to cells that express the IL-3 receptor, primarily certain malignant cells. Once inside these cells, the diphtheria toxin inhibits protein synthesis, leading to cell death. It is administered intravenously. Tagraxofusp is approved for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive hematologic malignancy. The drug works by binding to the CD123 receptor, which is found on the surface of BPDCN cells. This binding allows the drug to enter the cancer cells and deliver the toxic component, leading to their destruction. Common side effects can include infusion-related reactions, fluid retention, edema, nausea, and fatigue. Monitoring of liver and kidney function is typically recommended during treatment.